The genetically engineered, humanized, bispecific monoclonal antibody emicizumab (Hemlibra® ) that mimics the cofactor activity of activated FVIII has been approved for treatment of haemophilia A patients with and without inhibitor. In the pivotal pre-marketing clinical trials emicizumab prophylaxis significantly reduced bleeding rates compared to previous treatments and was well tolerated. However, a consequence of this novel therapy may be the host immune response to a foreign protein.
Characterization of the neutralizing anti-emicizumab antibody in a patient with haemophilia A and inhibitor / C. Valsecchi, M. Gobbi, M. Beeg, T. Adams, G. Castaman, L. Schiavone, J.A. Huntington, F. Peyvandi. - In: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. - ISSN 1538-7933. - 19:3(2021), pp. 711-718. [10.1111/jth.15226]
Characterization of the neutralizing anti-emicizumab antibody in a patient with haemophilia A and inhibitor
C. Valsecchi;F. Peyvandi
2021
Abstract
The genetically engineered, humanized, bispecific monoclonal antibody emicizumab (Hemlibra® ) that mimics the cofactor activity of activated FVIII has been approved for treatment of haemophilia A patients with and without inhibitor. In the pivotal pre-marketing clinical trials emicizumab prophylaxis significantly reduced bleeding rates compared to previous treatments and was well tolerated. However, a consequence of this novel therapy may be the host immune response to a foreign protein.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jth.15226.pdf
accesso riservato
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
11.03 MB
Formato
Adobe PDF
|
11.03 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
